Zacks: Brokerages Anticipate Epizyme, Inc. (NASDAQ:EPZM) Will Post Earnings of -$0.56 Per Share

Analysts forecast that Epizyme, Inc. (NASDAQ:EPZM) will post earnings of ($0.56) per share for the current quarter, according to Zacks. Four analysts have made estimates for Epizyme’s earnings, with estimates ranging from ($0.68) to ($0.44). Epizyme posted earnings per share of ($0.51) during the same quarter last year, which would indicate a negative year over year growth rate of 9.8%. The company is expected to report its next quarterly earnings results on Monday, May 3rd.

According to Zacks, analysts expect that Epizyme will report full year earnings of ($2.21) per share for the current fiscal year, with EPS estimates ranging from ($2.69) to ($1.74). For the next fiscal year, analysts expect that the firm will post earnings of ($1.65) per share, with EPS estimates ranging from ($2.12) to ($0.38). Zacks’ earnings per share averages are an average based on a survey of sell-side research analysts that cover Epizyme.

Epizyme (NASDAQ:EPZM) last released its quarterly earnings data on Monday, February 22nd. The biopharmaceutical company reported ($0.65) earnings per share for the quarter, missing the consensus estimate of ($0.59) by ($0.06). Epizyme had a negative return on equity of 83.45% and a negative net margin of 1,899.35%. The firm had revenue of $8.38 billion for the quarter, compared to the consensus estimate of $6.55 million. Epizyme’s revenue for the quarter was up 95.0% on a year-over-year basis.

A number of research analysts have weighed in on EPZM shares. Citigroup cut their price target on shares of Epizyme from $35.00 to $27.00 in a research note on Wednesday, February 24th. SVB Leerink reaffirmed a “market perform” rating on shares of Epizyme in a research note on Friday, February 5th. Credit Suisse Group assumed coverage on shares of Epizyme in a research note on Tuesday, March 30th. They issued an “outperform” rating and a $13.00 price target on the stock. Wedbush reissued an “outperform” rating on shares of Epizyme in a research report on Tuesday, February 23rd. Finally, Morgan Stanley restated an “equal weight” rating and issued a $14.00 price objective on shares of Epizyme in a report on Wednesday, March 3rd. Four equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus price target of $16.38.

EPZM traded down $0.01 during trading on Thursday, reaching $8.43. The company had a trading volume of 27,204 shares, compared to its average volume of 1,116,394. The company has a debt-to-equity ratio of 0.33, a current ratio of 8.95 and a quick ratio of 8.71. Epizyme has a 12 month low of $7.44 and a 12 month high of $22.00. The business’s fifty day moving average price is $9.21 and its 200 day moving average price is $11.31. The company has a market cap of $858.05 million, a P/E ratio of -3.75 and a beta of 1.76.

In other Epizyme news, CEO Robert B. Bazemore sold 6,069 shares of the firm’s stock in a transaction that occurred on Monday, January 25th. The shares were sold at an average price of $11.41, for a total transaction of $69,247.29. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Matthew Ros sold 2,872 shares of Epizyme stock in a transaction that occurred on Monday, January 25th. The shares were sold at an average price of $11.41, for a total transaction of $32,769.52. The disclosure for this sale can be found here. Insiders have sold 27,178 shares of company stock valued at $266,862 over the last 90 days. Company insiders own 16.30% of the company’s stock.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in EPZM. Metropolitan Life Insurance Co NY raised its position in shares of Epizyme by 18.3% in the first quarter. Metropolitan Life Insurance Co NY now owns 19,570 shares of the biopharmaceutical company’s stock valued at $242,000 after buying an additional 3,029 shares in the last quarter. FMR LLC increased its stake in Epizyme by 0.3% in the first quarter. FMR LLC now owns 3,484,137 shares of the biopharmaceutical company’s stock valued at $43,169,000 after acquiring an additional 11,759 shares during the last quarter. California Public Employees Retirement System increased its stake in Epizyme by 2.5% in the third quarter. California Public Employees Retirement System now owns 202,239 shares of the biopharmaceutical company’s stock valued at $2,413,000 after acquiring an additional 4,900 shares during the last quarter. BlackRock Inc. increased its stake in Epizyme by 1.0% in the third quarter. BlackRock Inc. now owns 7,672,267 shares of the biopharmaceutical company’s stock valued at $91,529,000 after acquiring an additional 75,982 shares during the last quarter. Finally, Swiss National Bank increased its stake in Epizyme by 1.8% in the third quarter. Swiss National Bank now owns 160,300 shares of the biopharmaceutical company’s stock valued at $1,912,000 after acquiring an additional 2,900 shares during the last quarter. Institutional investors own 89.82% of the company’s stock.

Epizyme Company Profile

Epizyme, Inc, a commercial-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases in the United States. The company offers Tazemetostat for the treatment of metastatic or locally advanced epithelioid sarcoma for adults and pediatric patients.

Read More: What does a hold rating mean?

Get a free copy of the Zacks research report on Epizyme (EPZM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Epizyme (NASDAQ:EPZM)

Receive News & Ratings for Epizyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme and related companies with MarketBeat.com's FREE daily email newsletter.